Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
Liu C, Cao Z, Yan H, Wong YJ, Xie Q, Hirooka M, Enomoto H, Kim TH, Hanafy AS, Liu Y, Huang Y, Li X, Kang N, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Jung YK, Yim HJ, Guo Y, Zhang L, Ma J, Kumar M, Jindal A, Teh KB, Sarin SK, Qi X. Liu C, et al. Among authors: enomoto h. Am J Gastroenterol. 2023 Jul 20. doi: 10.14309/ajg.0000000000002382. Online ahead of print. Am J Gastroenterol. 2023. PMID: 37467451 No abstract available.
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Kobayashi N, Tada T, Nishimura T, Matono T, Yuri Y, Takashima T, Aizawa N, Ikeda N, Fukunishi S, Hashimoto M, Ohyanagi M, Enomoto H, Iijima H. Kobayashi N, et al. Among authors: enomoto h. Hepatol Res. 2024 May;54(5):429-438. doi: 10.1111/hepr.13994. Epub 2023 Dec 13. Hepatol Res. 2024. PMID: 38015179
VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.
Matono T, Tada T, Nishimura T, Takashima T, Aizawa N, Ikeda N, Shiomi H, Enomoto H, Iijima H. Matono T, et al. Among authors: enomoto h. J Med Ultrason (2001). 2024 Apr;51(2):293-300. doi: 10.1007/s10396-023-01398-5. Epub 2023 Dec 26. J Med Ultrason (2001). 2024. PMID: 38147196
Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.
Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ioji T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, Koga H, Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T. Nakamura T, et al. Among authors: enomoto h. Regen Ther. 2024 May 4;27:455-463. doi: 10.1016/j.reth.2024.04.018. eCollection 2024 Dec. Regen Ther. 2024. PMID: 38737403 Free PMC article.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: enomoto h. Aliment Pharmacol Ther. 2024 May 8. doi: 10.1111/apt.18037. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38716823
738 results